CFH and hyperinsulinemic hypoglycemia, familial, 4: Complement activation through the alternative pathway (AP) is supported by the genetic evidence for the deposition of aPLA2R-Ab IgG4, C3, and C5b-9 in patients with MBL deficiency [96]; additionally, in patients with PLA2R-associated PMN, AP can be utilized via the production of antibodies targeting complement factor H (CFH) [97], a cell surface AP inhibitor [98,99].